Celldex Therapeutics (NQ: CLDX )
31.39 +0.21 (+0.69%) Streaming Delayed Price Updated: 11:31 AM EDT, May 31, 2023 Add to My Watchlist
All News about Celldex Therapeutics
4 Analysts Have This to Say About Celldex Therapeutics
Today 11:01 EDT
A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ: BRT) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market
May 11, 2023
Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike.
Celldex Therapeutics: Q1 Earnings Insights
May 04, 2023
Why Celldex Therapeutics Shares Are Trading Higher Today
February 27, 2023
Celldex Therapeutics Earnings Perspective: Return On Capital Employed
December 19, 2022
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
February 03, 2023
BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients
December 14, 2022
Small and big pharma companies such as Pfizer Inc. (NYSE: PFE), Celldex Therapeutics Inc. (NASDAQ: CLDX), and Hologic Inc. (NASDAQ: HOLX) are ramping up efforts to help reduce or eliminate the growing...
Celldex to Participate in Upcoming November Investor Conferences
November 10, 2022
HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here's What You Need To Know
July 01, 2022
HC Wainwright & Co. has decided to maintain its Buy rating of Celldex Therapeutics (NASDAQ:CLDX) and raise its price target from $60.00 to $73.00. Shares of Celldex Therapeutics are trading down 14.91%...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following